Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079365532> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2079365532 endingPage "9" @default.
- W2079365532 startingPage "1" @default.
- W2079365532 abstract "Rituximab, a genetically engineered monoclonal chimeric antibody, targets the CD20 antigen expressed on B cells. It was approved by the US Food and Drug Administration on November 26, 1997, for the indication of relapsed or refractory, CD20-positive, B-cell, low-grade or follicular non-Hodgkins lymphoma (LG/F NHL), and by the European Agency for the Evaluation of Medicinal Products on June 2, 1998, for therapy of patients with Stage III/IV, follicular, chemoresistant or relapsed NHL. Eight Phase II or III clinical trials in LG/F NHL patients have been completed five single-agent studies and three combination studies. Rituximab has a favorable safety profile most adverse events (AEs) are Grade 1 or 2, and the frequency of AEs decrease with subsequent infusions. AEs in the combination studies are consistent with those seen with individual agents. For evaluable patients in the single-agent studies, overall response rates (ORR) ranged from 40percent to 60percent, median duration of response (DR) r anged from 5.9 to 15.0+ months, and median time to progression (TTP) ranged from 8.1 to 19.4+ months. For evaluable patients in the combination studies, the ORR ranged from 45percent to 100percent, median DR ranged from 11.7+ to 39.1+ months, and median TTP ranged from 12.9+ to 40.5+ months. Studies in intermediate- and high-grade NHL are ongoing. Long-term development plans include evaluating the safety and efficacy of rituximab in various types of lymphoma and in combination with other lymphoma regimens. Future studies may explore ways to increase rituximab efficacy by upregulating CD20 or increasing effector function with different cytokines. Keywords: Rituximab, Monoclonal Antibody, Lymphoma, B cell, CD20 positive" @default.
- W2079365532 created "2016-06-24" @default.
- W2079365532 creator A5000927141 @default.
- W2079365532 creator A5001503483 @default.
- W2079365532 creator A5001835930 @default.
- W2079365532 creator A5021994315 @default.
- W2079365532 creator A5036961254 @default.
- W2079365532 creator A5067603439 @default.
- W2079365532 creator A5068725684 @default.
- W2079365532 creator A5075599709 @default.
- W2079365532 creator A5085812618 @default.
- W2079365532 creator A5086132292 @default.
- W2079365532 creator A5090641314 @default.
- W2079365532 date "2000-07-01" @default.
- W2079365532 modified "2023-10-01" @default.
- W2079365532 title "Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma" @default.
- W2079365532 cites W2028269517 @default.
- W2079365532 doi "https://doi.org/10.2174/1389201003379059" @default.
- W2079365532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11467356" @default.
- W2079365532 hasPublicationYear "2000" @default.
- W2079365532 type Work @default.
- W2079365532 sameAs 2079365532 @default.
- W2079365532 citedByCount "121" @default.
- W2079365532 countsByYear W20793655322012 @default.
- W2079365532 countsByYear W20793655322013 @default.
- W2079365532 countsByYear W20793655322014 @default.
- W2079365532 countsByYear W20793655322015 @default.
- W2079365532 countsByYear W20793655322016 @default.
- W2079365532 countsByYear W20793655322017 @default.
- W2079365532 countsByYear W20793655322018 @default.
- W2079365532 countsByYear W20793655322019 @default.
- W2079365532 countsByYear W20793655322020 @default.
- W2079365532 countsByYear W20793655322021 @default.
- W2079365532 countsByYear W20793655322022 @default.
- W2079365532 countsByYear W20793655322023 @default.
- W2079365532 crossrefType "journal-article" @default.
- W2079365532 hasAuthorship W2079365532A5000927141 @default.
- W2079365532 hasAuthorship W2079365532A5001503483 @default.
- W2079365532 hasAuthorship W2079365532A5001835930 @default.
- W2079365532 hasAuthorship W2079365532A5021994315 @default.
- W2079365532 hasAuthorship W2079365532A5036961254 @default.
- W2079365532 hasAuthorship W2079365532A5067603439 @default.
- W2079365532 hasAuthorship W2079365532A5068725684 @default.
- W2079365532 hasAuthorship W2079365532A5075599709 @default.
- W2079365532 hasAuthorship W2079365532A5085812618 @default.
- W2079365532 hasAuthorship W2079365532A5086132292 @default.
- W2079365532 hasAuthorship W2079365532A5090641314 @default.
- W2079365532 hasConcept C121332964 @default.
- W2079365532 hasConcept C126322002 @default.
- W2079365532 hasConcept C142424586 @default.
- W2079365532 hasConcept C143998085 @default.
- W2079365532 hasConcept C18031839 @default.
- W2079365532 hasConcept C197934379 @default.
- W2079365532 hasConcept C203014093 @default.
- W2079365532 hasConcept C2777058707 @default.
- W2079365532 hasConcept C2779338263 @default.
- W2079365532 hasConcept C2780653079 @default.
- W2079365532 hasConcept C535046627 @default.
- W2079365532 hasConcept C71924100 @default.
- W2079365532 hasConcept C87355193 @default.
- W2079365532 hasConcept C90924648 @default.
- W2079365532 hasConceptScore W2079365532C121332964 @default.
- W2079365532 hasConceptScore W2079365532C126322002 @default.
- W2079365532 hasConceptScore W2079365532C142424586 @default.
- W2079365532 hasConceptScore W2079365532C143998085 @default.
- W2079365532 hasConceptScore W2079365532C18031839 @default.
- W2079365532 hasConceptScore W2079365532C197934379 @default.
- W2079365532 hasConceptScore W2079365532C203014093 @default.
- W2079365532 hasConceptScore W2079365532C2777058707 @default.
- W2079365532 hasConceptScore W2079365532C2779338263 @default.
- W2079365532 hasConceptScore W2079365532C2780653079 @default.
- W2079365532 hasConceptScore W2079365532C535046627 @default.
- W2079365532 hasConceptScore W2079365532C71924100 @default.
- W2079365532 hasConceptScore W2079365532C87355193 @default.
- W2079365532 hasConceptScore W2079365532C90924648 @default.
- W2079365532 hasIssue "1" @default.
- W2079365532 hasLocation W20793655321 @default.
- W2079365532 hasLocation W20793655322 @default.
- W2079365532 hasOpenAccess W2079365532 @default.
- W2079365532 hasPrimaryLocation W20793655321 @default.
- W2079365532 hasRelatedWork W1579700026 @default.
- W2079365532 hasRelatedWork W1594335059 @default.
- W2079365532 hasRelatedWork W1991463943 @default.
- W2079365532 hasRelatedWork W1997629499 @default.
- W2079365532 hasRelatedWork W1999048711 @default.
- W2079365532 hasRelatedWork W2043813787 @default.
- W2079365532 hasRelatedWork W2062186653 @default.
- W2079365532 hasRelatedWork W2073341443 @default.
- W2079365532 hasRelatedWork W2412172283 @default.
- W2079365532 hasRelatedWork W3029070336 @default.
- W2079365532 hasVolume "1" @default.
- W2079365532 isParatext "false" @default.
- W2079365532 isRetracted "false" @default.
- W2079365532 magId "2079365532" @default.
- W2079365532 workType "article" @default.